LLY•Eli Lilly said third-quarter net income rose 16% to $6.45 billion as revenue climbed 39% to $24.4 billion. The company raised its full-year 2026 revenue guidance to $91 billion–$92 billion from $85 billion–$87 billion.
Eli Lilly’s third-quarter 2026 reported earnings rose 16% year over year to $7.22 per share, while revenue climbed 39% to $24.4 billion, driven primarily by Mounjaro and Zepbound. Mounjaro revenue jumped 65% to $10.72 billion, and Zepbound revenue increased 49% to $5.35 billion.
The company raised its full-year 2026 revenue guidance to $91 billion–$92 billion from $85 billion–$87 billion. Mounjaro also secured FDA approval to reduce cardiovascular risk in adults with type 2 diabetes.
